|| The term "post-transplant lymphoproliferative disorder" or disease (PTLD) was first introduced in 1984 by Starzl ( Starzl et al. 1984) .PTLDs are serious, life-threatening complications of solid-organ transplantation (SOT) and bone marrow transplantation, and are associated with high mortality. PTLDs represent a heterogeneous group of lymphoproliferative diseases, which show a spectrum of clinical, morphologic, and molecular genetic features ranging from reactive polyclonal lesions to frank lymphomas.|
PTLDs are classified into early lesions, polymorphic, monomorphic, and classical Hodgkin's lymphoma-like PTLD.
P CHL type PTLD occurs in the post-transplant setting, most often in renal transplant patients, composed of variable numbers of HRS cells admixed with a rich inflammatory background. The composition of the reactive cellular infiltrate varies according to the histological subtype (Swerdlow, et al ,2008. Mucha, et al. 2010.).
|Phenotype / cell stem origin
|| The majority (>90%) of PTLD in solid organ recipients are of host origin and only a minority of donor origin. Donor origin PTLD appear to be most common in liver and lung allograft recipients, and frequently involve the allograft. In contrast, the majority of PTLD in bone marrow (BM) allograft recipients are of donor origin, as would be expected, since successful engraftment results in an immune system that is nearly exclusively of donor origin (Chadbum, et al ,1995. Swerdlow, et al ,2008). |
Phenotypically, CHL type PTLD cases show CD30+,CD15+,CD20- in HRS cells, but some cases are CD15-.Because RS like cells may be seen in early, polymorphic and some monomorphic PTLD, the diagnosis of CHL must be distinguished from Hodgkin like lesions, in which the EBV+ RS like cells are CD45+, CD30+, CD15-, CD20+ and small to intermediate-sized EBV+ lymphoid cells can be seen as well (werdlow, et al ,2008. Pitman et al,2006. Ranfanathan, et al, 2004).
|Epidemiology|| The incidence of PTLD ranges from 1-3 % in renal to 5-20 % in lung and intestinal transplantation, related to the type of transplanted organ, intensity of IS, age, and viral infection, etc. ( Opelz, 2003. Opelz,1993). In contrast, the incidence of PTLD after BMT is about 1.0 % for recipients from HLA-compatible related donors (lower than that of SOT), but in up to 25 % for high-risk patients (Curtis, 1999). However, the field has evolved during the last decade. Hoegh-Petersen et al. found a frequency of 8.1 % among 307 allo-HSCT recipients who had also received ATG-based conditioning. Kamani et al. found an overall incidence of 2.3 % for post-transplant malignancy (most of which were PTLD) in patients receiving such transplant for primary immunodeficiency disorders. The highest subgroup, those patients with Wiskott-Aldrich syndrome, had a 3.3 % frequency. |
In our hospital, it is 1.5 % (9/585) from August 2002 to October 2006 and about 1 % (9/857) from November 2006 to November 2009 after allo-HSCT, respectively. The incidence of PTLD was higher in mismatched or unrelated HSCT group than that of conventional one, 3.4 % (7/208), 2.3 % (1/44) versus 0/323. It was also higher in patients with conditioning regimen including ATG than those without, 3.4 % (9/262) vs. 0/323. CHL type PTLD is the least common major form of PTLD (Swerdlow, et al ,2008. Chen, et al ,2013).
|Clinics|| The clinical features of PTLD differ from those of lymphomas observed in the general population. Symptoms may be mild, such as fever, mononucleosis-like syndrome, lymphadenopathy, recurrent infections or severe organ dysfunction. The variable manifestation of PTLD depends on many factors, such as the type of transplanted organ or IS used, histopathology and time elapsed since transplantation. The first year after transplantation is important, in lung recipients, more than 50 % of all PTLDs develop during the first post-transplant year. Our data showed that 88.2 % of patients (15/17) were diagnosed within 7 months after transplantation (1.5-7 months), and the median interval after transplantation to the diagnosis was 2.5 months (mean 4.7 months, range 1.5-19 months), shorter than that of SOT. The frequent sites of PTLD include GI (jejunum more often than colon), lymph nodes, and central nervous system, different from type to type of transplantation (Opelz, et al, 2003. Swerdlow, et al ,2008).|
|Pathology|| CHL type PTLD is characterized by effacement of the architecture and composed of variable numbers of HRS cells admixed with a rich inflammatory background. The composition of the reactive cellular infiltrate varies according to the histological subtype. The diagnosis of CHL must be distinguished from Hodgkin like lesions, in which the EBV+ RS like cells are CD45+, CD30+, CD15-, CD20+ and small to intermediate-sized EBV+ lymphoid cells can be seen as well, especially from polymorphic PTLD, and the overall morphologic features should be depended on. |
There are four histologic subtypes of classical Hodgkin lymphomas,, i.e. nodular sclerosis cHL, mixed cellularity cHL, lymphocyte-rich cHL, and lymphocyte depleted cHL, according to their cellularity and background. MC subtype is most common.
| Figure 1. Hodgkin type PTLD. Effacement of the architecture and HRS cells surrounded by small lymphocytes, neutrophils and eosinophils ( HE stain).|
| Figure 2. HRS cells are positive for CD30.|
| Figure 3. Some HRS cells are positive for CD15.|
| Figure 4. HRS cells are positive for EBER (in situ hybridization).|
|Treatment|| There is no consensus on the optimal treatment of PTLD. It is generally agreed that three major strategies should be applied: restoration of the recipient's immunity (to limit the EBV infection), elimination EBV and removal of neoplastic B cells. Reduction of IS or even withdrawal remains the first-line treatment. With reduction of immunosuppression, virtually all early lesions regress and generally show good prognosis, whereas half of P-PTLD regress and some will progress, the majority of M-PTLDs do not regress. DLI was effectively used in EBV-associated PTLD after mismatched/haploidentical haematopoietic stem cell transplantation (HSCT). Patients with lymph node localization have a relatively good outcome, and disseminated disease in contrast has a poor prognosis (Mucha, et al, 2010. Xu, et al, 2010). |
Staging of CHL type PTLD determines the mode of therapy.
|Prognosis|| The prognosis of PTLD is poor. The treatment of rejection episodes with OKT3 or ATG enhances the PTLD risk in patients who did not receive antibody induction, rejection therapy with OKT3 or ATG adds to the already increased lymphoma risk HLA matching is also a risk factor in the pathogenesis of PTLD, and HLA-B or HLA-DR mismatches especially seem to be critical. The number of HLA mismatches parallels with an increased risk of PTLD (Opelz, et al, 2003> Īpelz, et al, 2010). |
Both clinical and laboratory parameters of CHL type PTLD are relevant to prognosis. histologic subtype is less important as a predictive factor (Allemani, et al, 2006).
| Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW; EUROCARE Working Group|
| Hodgkin disease survival in Europe and the U S|
| Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin|
| Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM|
| Am J Pathol 1995 Dec;147(6):1862-70|
| Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation|
| Chen DB, Song QJ, Chen YX, Chen YH, Shen DH|
| Int J Hematol 2013 Jan;97(1):117-24|
| Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study|
| Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ|
| Blood 1999 Oct 1;94(7):2208-16|
| Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma|
| Melzner I, Weniger MA, Menz CK, Möller P|
| Leukemia 2006 Jan;20(1):157-8|
| Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant|
| Mucha K, Foroncewicz B, Ziarkiewicz-Wróblewska B, Krawczyk M, Lerut J, Paczek L|
| 2010 Jul;25(7):2089-98 doi: 10|
| Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation|
| Opelz G, Döhler B|
| Transplantation 2010 Mar 15;89(5):567-72|
| Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients|
| Opelz G, Henderson R|
| Lancet 1993 Dec 18-25;342(8886-8887):1514-6|
| Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically|
| Pitman SD, Huang Q, Zuppan CW, Rowsell EH, Cao JD, Berdeja JG, Weiss LM, Wang J|
| Am J Surg Pathol 2006 Apr;30(4):470-6|
| Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma? Pediatr Dev Pathol|
| Ranganathan S, Webber S, Ahuja S, Jaffe R|
| 2004 Jul-Aug;(4):#4¸-60 Epub 2004 Jun 17|
| Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy|
| Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL, et al|
| Lancet 1984 Mar 17;1(8377):583-7|
| Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.|
| Swerdlow SH, Webber SA, Chadburn A, et al.|
| Lyon : IARC press; 2008: 343-349. ISBN:978-92-832-2431-0|
| [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation]|
| Xu LP, Liu DH, Liu KY, Chen H, Han W, Wang Y, Wang J, Shi HX, Huang XJ|
| Zhonghua Nei Ke Za Zhi 2010 Nov;49(11):955-8|